Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2024-02-20 6:57 pm Sale | 2023-02-16 | 13D | Galera Therapeutics, Inc. GRTX | Sofinnova Venture Partners IX L.P. | 0 0.000% | -3,083,712 (Position Closed) | Filing History |
| 2023-02-03 7:04 pm Sale | 2022-11-09 | 13D | Galera Therapeutics, Inc. GRTX | Sofinnova Venture Partners IX L.P. | 3,083,712 10.800% | -1,098 (-0.04%) | Filing History |
| 2021-03-04 06:17 am Sale | 2020-08-06 | 13D | Entasis Therapeutics Holdings Inc. ETTX | Sofinnova Venture Partners IX L.P. | 0 0.000% | -1,180,178 (Position Closed) | Filing History |
| 2020-08-19 11:58 am Purchase | 2020-08-11 | 13D | Checkmate Pharmaceuticals, Inc. CMPI | Sofinnova Venture Partners IX L.P. | 3,606,707 16.800% | 3,606,707 (New Position) | Filing History |
| 2020-06-05 4:48 pm Sale | 2020-06-02 | 13D | Iterum Therapeutics plc ITRM | Sofinnova Venture Partners IX L.P. | 410 0.000% | -115,101 (-99.64%) | Filing History |